Acute inhibition of excessive mitochondrial fission after myocardial infarction prevents long-term cardiac dysfunction


Autoria(s): Disatnik, Marie-Hélène; Ferreira, Julio Cesar Batista; Campos, Juliane Cruz; Gomes, Katia Maria Sampaio; Dourado, Paulo M .M.; Qi, Xin; Mochly-Rosen, Daria; dourado, paulo
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

14/03/2014

14/03/2014

08/10/2013

Resumo

BACKGROUND: Ischemia and reperfusion (IR) injury remains a major cause of morbidity and mortality and multiple molecular and cellular pathways have been implicated in this injury. We determined whether acute inhibition of excessive mitochondrial fission at the onset of reperfusion improves mitochondrial dysfunction and cardiac contractility postmyocardial infarction in rats. METHODS AND RESULTS: We used a selective inhibitor of the fission machinery, P110, which we have recently designed. P110 treatment inhibited the interaction of fission proteins Fis1/Drp1, decreased mitochondrial fission, and improved bioenergetics in three different rat models of IR, including primary cardiomyocytes, ex vivo heart model, and an in vivo myocardial infarction model. Drp1 transiently bound to the mitochondria following IR injury and P110 treatment blocked this Drp1 mitochondrial association. Compared with control treatment, P110 (1 μmol/L) decreased infarct size by 28 ± 2% and increased adenosine triphosphate levels by 70+1% after IR relative to control IR in the ex vivo model. Intraperitoneal injection of P110 (0.5 mg/kg) at the onset of reperfusion in an in vivo model resulted in improved mitochondrial oxygen consumption by 68% when measured 3 weeks after ischemic injury, improved cardiac fractional shortening by 35%, reduced mitochondrial H2O2 uncoupling state by 70%, and improved overall mitochondrial functions. CONCLUSIONS: Together, we show that excessive mitochondrial fission at reperfusion contributes to long-term cardiac dysfunction in rats and that acute inhibition of excessive mitochondrial fission at the onset of reperfusion is sufficient to result in long-term benefits as evidenced by inhibiting cardiac dysfunction 3 weeks after acute myocardial infarction.

Sao Paulo Research Foundation (FAPESP 2012/05765-2)

The National Council for Scientific and Technological Development (CNPq 470880/2012-0)

Identificador

Journal of the American Heart Association, Oxford, v.2, n.5, p.e000461, 2013

http://www.producao.usp.br/handle/BDPI/44127

10.1161/JAHA.113.000461

http://dx.doi.org/10.1161/JAHA.113.000461

Idioma(s)

eng

Publicador

Wiley-Blackwell

Oxford

Relação

Journal of the American Heart Association

Direitos

openAccess

http://creativecommons.org/licenses/by-nc/3.0/br/

2013 The Authors

Palavras-Chave #Cardiac Myocytes #Drp1 #Heart #Mitochondria #Protein-protein interaction inhibitor #Coração #Mitocondrias #Proteínas #Infarto do miocárdio
Tipo

article

original article

publishedVersion